Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13101963 | 0.90 | ALDH1A1 (0.58) | ALDH1A1HTTLMNASMN1; SMN2GPR139 | |
| SCHEMBL13101690 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HTTLMNASMN1; SMN2GPR139 | |
| SCHEMBL13283006 | 0.88 | RAB9A (0.53) | ALDH1A1HTTLMNASMN1; SMN2GPR139 | |
| SCHEMBL13102046 | 0.87 | ALDH1A1 (0.51) | ALDH1A1HTTLMNASMN1; SMN2P2RY14 | |
| SCHEMBL13282920 | 0.86 | NPSR1 (0.53) | ALDH1A1HTTLMNASMN1; SMN2P2RY14 | |
| SCHEMBL13101962 | 0.86 | KDM4E (0.53) | ALDH1A1HTTLMNASMN1; SMN2GPR139 | |
| SCHEMBL13282989 | 0.85 | NPSR1 (0.56) | ALDH1A1HTTLMNASMN1; SMN2P2RY14 | |
| SCHEMBL13101952 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HTTLMNASMN1; SMN2GPR139 | |
| SCHEMBL13102204 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HTTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL13102210 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HTTLMNASMN1; SMN2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663237-B1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7741332-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1663237-A4 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7223768-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1663237-A2 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005025293-A2 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059823-A1 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885HTT 329/4885LMNA 1121/4885 |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885HTT 329/4885LMNA 1121/4885 |
| US-20050059823-A1 | Fused ring heterocycles as potassium channel modulators | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885HTT 329/4885LMNA 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.